Get started

PharmaEssentia (Japan)

Alternate names: PharmaEssentia Japan KK, ファーマエッセンシアジャパン
ROR: 05qvcw226
OpenAlex ID: I4405285591
SURPASS-ET: phase III Study of Ropeginterferon Alfa-2b versus Anagrelide as Second-Line Therapy in Essential Thrombocythemia
2022 · Srdan Verstovsek, Norio Komatsu, et al. · Future Oncology · 39
Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study
2022 · Yoko Edahiro, Kohshi Ohishi, et al. · International Journal of Hematology · 39
A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera
2023 · Jie Jin, Lei Zhang, et al. · Experimental Hematology and Oncology · 31
PDF
Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration
2021 · Narihisa Miyachi, Oleh Zagrijtschuk, et al. · Clinical Drug Investigation · 30
Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment
2024 · Shan Shan Suo, Rong Feng Fu, et al. · Journal of Hematology · 26
PDF
Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study
2025 · Ruben Mesa, Harinder Gill, et al. · The Lancet Haematology · 17
A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis
2024 · Ghaith Abu-Zeinah, Albert Qin, et al. · Annals of Hematology · 16
PDF
Clinical characteristics, prognostic factors, and outcomes of patients with essential thrombocythemia in Japan: the JSH-MPN-R18 study
2021 · Yoshinori Hashimoto, Tomoki Ito, et al. · International Journal of Hematology · 16
Impact of non‐driver gene mutations on thrombo‐haemorrhagic events in ET patients
2023 · Chiho Furuya, Soji Morishita, et al. · British Journal of Haematology · 14
PDF
Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera
2024 · Keita Kirito, Yuka Sugimoto, et al. · International Journal of Hematology · 13
PDF
Population Pharmacokinetics‐Pharmacodynamics and Exposure‐Response of Ropeginterferon Alfa‐2b in Chinese and Japanese Patients With Polycythemia Vera
2025 · Albert Qin, Kazuya Shimoda, et al. · Pharmacology Research & Perspectives · 10
Reevaluation of cardiovascular risk factors for thrombotic events in 580 Japanese patients with essential thrombocythemia
2022 · Chiho Furuya, Yoshinori Hashimoto, et al. · Journal of Thrombosis and Thrombolysis · 10
Non‐driver gene mutation analysis in a large cohort of polycythemia vera and essential thrombocythemia
2022 · Soji Morishita, Yoshinori Hashimoto, et al. · European Journal Of Haematology · 10
Clinical characteristics of Japanese patients with polycythemia vera: results of the JSH-MPN-R18 study
2022 · Yoko Edahiro, Tomoki Ito, et al. · International Journal of Hematology · 9
Ethnic sensitivity analyses of pharmacokinetics, efficacy and safety in polycythemia vera treatment with ropeginterferon alfa-2b
2024 · Albert Qin, Daoxiang Wu, et al. · Frontiers in Pharmacology · 8
PDF
Ropeginterferon alfa-2b shows anti-polycythaemia vera activity without causing clinically significant anaemia
2024 · Keita Kirito, Albert Qin, et al. · BJC Reports · 7
PDF
Efficacy and safety outcomes in Japanese patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b
2024 · Kazuya Shimoda, Albert Qin, et al. · International Journal of Hematology · 6
MPL gene mutation is a possible risk factor for thrombosis in patients with essential thrombocythemia in Japan
2023 · Chiho Furuya, Yoshinori Hashimoto, et al. · Hematology · 6
PDF
Clinical features of acquired erythrocytosis: Low levels of serum erythropoietin in a subset of non‐neoplastic erythrocytosis patients
2022 · Yosuke Mori, Marito Araki, et al. · Cancer Medicine · 6
PDF
Clinical characteristics in adolescents and young adults with polycythemia vera and essential thrombocythemia in Japan
2024 · Yuka Sugimoto, Keiki Nagaharu, et al. · International Journal of Hematology · 5
Ropeginterferon alfa-2b versus anagrelide for the treatment of essential thrombocythemia: Topline results of the phase 3 SURPASS-ET trial.
2025 · Ruben A. Mesa, Harinder Gill, et al. · Journal of Clinical Oncology · 4
PDF
Ropeginterferon-α2b discontinuation after long-term exposure: four cases from a single institution
2025 · Shuichi Shirane, Tadaaki Inano, et al. · International Journal of Hematology · 4
MPN-545 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs. Anagrelide as Second Line Therapy in Essential Thrombocythemia
2022 · Ruben Mesa, Norio Komatsu, et al. · Clinical Lymphoma Myeloma & Leukemia · 4
Iron deficiency and phlebotomy in patients with polycythemia vera
2024 · Yoko Edahiro, Norio Komatsu · International Journal of Hematology · 3
Efficacy and safety of a three-step dose escalation regimen of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: a phase 3b, single-arm, multicenter study
2026 · Tadaaki Inano, Yuka Sugimoto, et al. · International Journal of Hematology · 2
PDF
Works count: 0
Citation count:
Year
Topic
Type